Literature DB >> 22403018

Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders.

Ian E Alexander1, Cindy Kok, Allison P Dane, Sharon C Cunningham.   

Abstract

Many metabolic diseases are compelling candidates for gene therapy, and are the subject of vigorous pre-clinical research. Successful phenotype correction in mouse models is now commonplace and research effort is increasingly being directed towards addressing the translational challenges inherent in human clinical trials. This paper places current efforts to develop gene therapy approaches to metabolic disease in historical context and describes contemporary research in the authors' laboratory on urea cycle defects, particularly ornithine transcarbamylase deficiency, in a manner that is illustrative of the general state of the field.

Entities:  

Mesh:

Year:  2012        PMID: 22403018     DOI: 10.1007/s10545-012-9467-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  33 in total

1.  Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation.

Authors:  Allison P Dane; Sharon C Cunningham; Nicole S Graf; Ian E Alexander
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

2.  Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease.

Authors:  I A Qureshi; J Letarte; R Ouellet
Journal:  Pediatr Res       Date:  1979-07       Impact factor: 3.756

3.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

Review 4.  The ethics of gene therapy: balancing the risks.

Authors:  Claire T Deakin; Ian E Alexander; Ian Kerridge
Journal:  Curr Opin Mol Ther       Date:  2010-10

5.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

6.  Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

Authors:  S E Raper; J M Wilson; M Yudkoff; M B Robinson; X Ye; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

7.  Gene delivery to the juvenile mouse liver using AAV2/8 vectors.

Authors:  Sharon C Cunningham; Allison P Dane; Afroditi Spinoulas; Grant J Logan; Ian E Alexander
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

Review 8.  Clinical gene therapy using recombinant adeno-associated virus vectors.

Authors:  C Mueller; T R Flotte
Journal:  Gene Ther       Date:  2008-04-17       Impact factor: 5.250

9.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  2 in total

1.  Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia.

Authors:  M A Torres-Vega; R Y Vargas-Jerónimo; A G Montiel-Martínez; R M Muñoz-Fuentes; A Zamorano-Carrillo; A R Pastor; L A Palomares
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

2.  Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes.

Authors:  Samantha L Ginn; Anais K Amaya; Sophia H Y Liao; Erhua Zhu; Sharon C Cunningham; Michael Lee; Claus V Hallwirth; Grant J Logan; Szun S Tay; Anthony J Cesare; Hilda A Pickett; Markus Grompe; Kimberley Dilworth; Leszek Lisowski; Ian E Alexander
Journal:  JHEP Rep       Date:  2019-12-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.